Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
psychopraxis. neuropraxis
Erschienen in:

01.09.2016 | Psychiatrie

Zur Therapie von ADHS bei komorbiden Autismus-Spektrum-Störungen

verfasst von: Univ.-Prof. Dr. Luise Poustka

Erschienen in: psychopraxis. neuropraxis | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

Autismus-Spektrum-Störungen (ASS) galten lange als Ausschlusskriterium für die Diagnose einer ADHS. Nach DSM-5 besteht nun die Möglichkeit, eine ADHS zusammen mit ASS zu diagnostizieren. Kinder mit der Doppeldiagnose ASS + ADHS zeigen insgesamt mehr Beeinträchtigungen sowohl hinsichtlich ihrer allgemeinen Psychopathologie als auch ihres Funktionsniveaus. Durch die Differenzierung von Patienten mit ASS mit zusätzlicher ADHS-Symptomatik und Patienten ohne ADHS-Symptomatik wird klinisch eine differenzierte Behandlung der individuellen Psychopathologie erleichtert. In folgendem Beitrag werden evidenzbasierte Therapieoptionen, vor allem in pharmakologischer Hinsicht, für von beiden Störungen Betroffene dargestellt.
Vorheriger Artikel Panorama
Nächster Artikel M. Parkinson: L-Dopa nach wie vor wirksamste Therapie
Literatur
1.
Arnold LE, Aman MG, Cook AM et al (2006) Atomoxetine for hyperactivity in autism spectrum disorders: Placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry 45:1196–1205CrossRefPubMed
2.
Baird G, Simonoff E, Pickles A, Chandler S, Loucas T, Meldrum D, Charman T (2006) Prevalence o disorders of the autism spectrum in a population cohort of children in South Thames: The Special Needs and Autism Project (SNAP). Lancet 368(9531):210–215CrossRefPubMed
3.
Bloch M, Qawasmi A (2011) Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: Systematic review and meta-analysis. J Am Acad Child Adolesc Psychiatry 50(10):991–1000CrossRefPubMedPubMedCentral
4.
Choque Olsson N, Rautio D, Asztalos J, Stoetzer U, Bölte S (2016) Social skills group training in high-functioning autism: a qualitative responder study. Autism. doi:10.​1177/​1362361315621885​
5.
Cortese S, Castelnau P, Morcillo C, Roux S, Bonnet-Brilhault F (2012) Psychostimulants for ADHD-like symptoms in individuals with autism spectrum disorders. Expert Rev Neurother 12(4):461–73
6.
Di Martino A, Melis G, Cianchetti C, Zuddas A (2004) Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: An open-pilot study. J Child Adolesc Psychopharmacol 14:207–218CrossRefPubMed
7.
Fernández de la Cruz L, Simonoff E, McGough JJ, Halperin JM, Arnold LE, Stringaris A (2015) Treatment of children with attention-deficit/hyperactivity disorder (ADHD) and irritability: Results from the multimodal treatment study of children with ADHD (MTA). J Am Acad Child Adolesc Psychiatry 54(1):62–70CrossRefPubMedPubMedCentral
8.
Friedrich EV, Sivanathan A, Lim T, Suttie N, Louchart S, Pillen S, Pineda JA (2015) An effective neurofeedback intervention to improve social interactions in children with autism spectrum disorder. J Autism Dev Disord 45(12):4084–4100. doi:10.​1007/​s10803-015-2523-5 CrossRefPubMed
9.
Gadow KD, Devincent CJ, Pomeroy J (2006) ADHD symptom subtypes in children with pervasive developmental disorder. J Autism Dev Disord 36:271–283CrossRefPubMed
10.
Grzadzinski R, Di Martino A, Brady E et al (2010) Examining autistic traits in children with ADHD: Does the autism spectrum extend to ADHD? J Autism Dev Disord 41(9):1178–1191. doi:10.​1007/​s10803-010-1135-3 CrossRef
11.
Handen BL, Johnson CR, Lubetsky M (2000) Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord 30:245–255CrossRefPubMed
12.
Harfterkamp M, van de Loo-Neus Minderaa GR et al (2012) A randomized doubleblind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry 51:733–741CrossRefPubMed
13.
Hartley S, Sikora D (2009) Which DSM-IV-TR criteria best differentiate high-functioning autism spectrum disorder from ADHD and anxiety disorders in older children? Autism 13(5):485–509PubMedPubMedCentral
14.
Holtmann M, Sonuga-Barke E, Cortese S, Brandeis D (2014) Neurofeedback for ADHD. Child Adolesc Psychiatr Clin N Am 23(4):789–806CrossRefPubMed
15.
Holtmann M, Steiner S, Hohmann S, Poustka L, Banaschewski T, Bölte S (2011) Neurofeedback in autism spectrum disorders. Dev Med Child Neurol 53(11):986–993CrossRefPubMed
16.
Holtmann M, Bolte S, Poustka F (2007) Attention deficit hyperactivity disorder symptoms in pervasive developmental disorders: association with autistic behavior domains and coexisting psychopathology. Psychopathology 40:172–177CrossRefPubMed
17.
Iizuka C, Yamashita Y, Nagamitsu S, Yamashita T, Araki Y, Ohya T et al (2010) Comparison of the strengths and difficulties questionnaire (SDQ) scores between children with high-functioning autism spectrum disorder (HFASD) and attention-deficit/hyperactivity disorder (AD/HD). Brain Dev 32(8):609–612CrossRefPubMed
18.
James S, Montgomery P, Williams K (2011) Omega-3 fatty acids supplementation for autism spectrum disorders (ASD). Cochrane Database Syst Rev 9:CD007992
19.
Jahromi LB, Kasari CL, McCracken JT et al (2009) Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity. J Autism Dev Disord 39:395–404CrossRefPubMed
20.
McCracken JT, Badashova KK, Posey DJ, Aman MG, Scahill L, Tierney E, Arnold LE, Vitiello B, Whelan F, Chuang SZ, Davies M, Shah B, McDougle CJ, Nurmi EL (2014) Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders. Pharmacogenomics J 14(3):295–302CrossRefPubMed
21.
Mankad D, Dupuis A, Smile S, Roberts W, Brian J, Lui T et al (2015) A randomized, placebo controlled trial of omega-3 fatty acids in the treatment of young children with autism. Mol Autism 6(1):18CrossRefPubMedPubMedCentral
22.
Nijmeijer JS, Arias-Vasquez A, Rommelse NN et al (2010) Identifying loci for the overlap between attention-deficit/hyperactivity disorder and autism spectrum disorder using a genome-wide QTL linkage approach. J Am Acad Child Adolesc Psychiatry 49:675–685PubMedPubMedCentral
23.
Penzner JB, Dudas M, Saito E et al (2009) Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality. J Child Adolesc Psychopharmacol 19:563–573CrossRefPubMedPubMedCentral
24.
Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA (2007) The worldwide prevalence of ADHD: A systematic review and metaregression analysis. Am J Psychiatry 164(6):942–948 (Review)CrossRefPubMed
25.
Posey DJ, Wiegand RE, Wilkerson J, Maynard M, Stigler KA, McDougle CJ (2006) Open-label atomoxetine for attention-deficit/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. J Child Adolesc Psychopharmacol 16:599–610CrossRefPubMed
26.
Rao PA, Landa RJ (2013) Association between severity of behavioral phenotype and comorbid attention deficit hyperactivity disorder symptoms in children with autism spectrum disorders. Autism 18:272–280CrossRefPubMedPubMedCentral
27.
Reichow B, Steiner A, Volkmar F (2012) Cochrane Review: social skills groups for people aged 6 to 21 with autism spectrum disorders (ASD). Evid Based Child Health 8(2):266–315CrossRef
28.
Ronald A, Simonoff E, Kuntsi J et al (2008) Evidence for overlapping genetic influences on autistic and ADHD behaviours in a community twin sample. J Child Psychol Psychiatry 49:535–542CrossRefPubMed
29.
RUPP Autism Network (2005) Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 62:1266–1274CrossRef
30.
Santosh PJ, Baird G, Pityaratstian N, Tavare E, Gringras P (2006) Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study. Child Care Health Dev 32:575–583
31.
Scahill L, McCracken JT, King BH, Rockhill C, Shah B, Politte L, Sanders R, Minjarez M, Cowen J, Mullett J, Page C, Ward D, Deng Y, Loo S, Dziura J, McDougle CJ, Research Units on Pediatric Psychopharmacology Autism Network (2015) Extended-release guanfacine for hyperactivity in children with autism spectrum disorder. Am J Psychiatry 172(12):1197–1206. doi:10.​1176/​appi.​ajp.​2015.​15010055 CrossRefPubMed
32.
Simonoff E, Pickles A, Charman T et al (2008) Psychiatric disorders in children with autism spectrum disorders: Prevalence, comorbidity, and associated factors in a population-derived sample. J Am Acad Child Adolesc Psychiatry 47:921–929CrossRefPubMed
33.
Simonoff E, Taylor E, Baird G, Bernard S, Chadwick O, Liang H, Whitwell S, Riemer K, Sharma K, Sharma SP, Wood N, Kelly J, Golaszewski A, Kennedy J, Rodney L, West N, Walwyn R, Jichi F (2013) Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability. J Child Psychol Psychiatry 54(5):527–535CrossRefPubMed
34.
Troost PW, Steenhuis MP, Tuynman-Qua HG et al (2006) Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: A pilot study. J Child Adolesc Psychopharmacol 16:611–619CrossRefPubMed
35.
Yoshida Y, Uchiyama T (2004) The clinical necessity for assessing Attention Deficit/Hyperactivity Disorder (AD/HD) symptoms in children with high-functioning Pervasive Developmental Disorder (PDD). Eur Child Adolesc Psychiatry 13(5):307–314CrossRefPubMed
Metadaten
Titel
Zur Therapie von ADHS bei komorbiden Autismus-Spektrum-Störungen
verfasst von
Univ.-Prof. Dr. Luise Poustka
Publikationsdatum
01.09.2016
Verlag
Springer Vienna
Erschienen in
psychopraxis. neuropraxis / Ausgabe 4/2016
Print ISSN: 2197-9707
Elektronische ISSN: 2197-9715
DOI
https://doi.org/10.1007/s00739-016-0337-7

Weitere Artikel der Ausgabe 4/2016

Panorama

  • Panorama

Dystonie

  • Neurologie

M. Parkinson: L-Dopa nach wie vor wirksamste Therapie

  • Open Access
  • Neurologie

Das Restless-Legs-Syndrom

  • Open Access
  • Neurologie

Effekte regionaler Psychosomatiktherapiemodule

  • Open Access
  • Psychiatrie

Benzodiazepine im Fokus

  • Psychiatrie